On March 15, 2024, Innolake Biopharm was granted the award of “Enterprise of Innovation Breakthrough in 2023” at BioChina2024 (EBC) Conference, which had 28,000 attendees. It is the second year for Innolake to win the innovation breakthrough award, based on the company’s efficient and sustainable innovation. The winner of this award was selected by the EBC commission and the experts panel based on evaluation of companies in the industry from two perspectives, i.e. the overall performance (the company fundamental, position in industry, innovation value of projects, business model, revenue, etc.) and its competitiveness in the industry (comprehensive background, brand influence, management competencies and the team of core experts).

Winning the award of "Enterprise of Innovation Breakthrough in 2023" is not only the recognition from the industry for Innolake’s innovative achievements in drug candidate development for anti-cancer and auto-immune disease, but also the commendation for Innolake’s sustained and efficient innovation.